Investigational drug · Phase 2
narmafotinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Cancer Metastatic.
Phase 2Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "narmafotinib"
First trial start
2025
Aug 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "narmafotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer Metastatic
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "narmafotinib" as an intervention, largest first.
- A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic CancerActive, not recruiting
Amplia Therapeutics LimitedIndustry
NCT07026279 · 67 participants (planned) · Start Aug 18, 2025 · Primary completion Jul 2029
Drug: narmafotinib ascending doses; narmafotinib dose comparison · For: Pancreatic Cancer Metastatic
Sites: St Leonards, Australia; Richmond, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Cancer Metastatic
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- SBP-101ivospeminPhase 31 trial
Panbela Therapeutics, Inc. · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- PelareorepPhase 23 trials
Oncolytics Biotech · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- ERAS-0015Phase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
- vopimetostatPhase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.